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We report a case of a female, born in 1952, diagnosed 
with a rare multiple endocrine neoplasia type 1 
(MEN1) gene variant of uncertain clinical significance 
(p.Val167Ala) presenting with acromegaly, late-onset 
primary hyperparathyroidism (PHP), and bilateral 
adrenal tumours (Fig. 1).
The diagnosis of acromegaly due to pituitary mac-
roadenoma was confirmed at the age of 45 years. The 
patient underwent a transsphenoidal resection of the 
pituitary tumour, with histopathological confirmation 
of adenoma chromophobe, which failed to achieve 
biochemical control of the disease. The patient refused 
consent to the second surgical approach or adjuvant 
radiotherapy. In 2002, pharmacological treatment with 
long-acting somatostatin analogue was introduced, 
resulting in successfully normalised insulin-like growth 
factor and growth hormone values.
Mild hypercalcaemia was discovered for the first 
time during endocrinological follow-up at the age of 
56 years (2.61 mmol/L, normal range 2.15–2.55 mmol/l), 
with elevated parathyroid hormone level (PTH) (87.4 
pg/mL, normal range 14.90–56.90) and increased urine 
excretion of calcium (7.01 mmol/24 h). 99mTc-MIBI 
single-photon emission computed tomography/com-
puted tomography (SPECT/CT) showed no typical focal 
accumulation of the tracer, only an increased uptake in 
the topography of the upper right parathyroid. Further 
follow-up of hypercalcaemia was planned. 
The radiological image of the hypothalamic-pituitary 
area remained stable since medical treatment implemen-
tation: the last pituitary magnetic resonance imaging 
(MRI) in 2015 showed the remnants of the pituitary 
gland, less than 1 mm in diameter, at the bottom of 
the sella turcica and two hypointense masses enhanc-
ing heterogeneously after contrast administration: 
11 × 8 × 13 mm in the right lateral part of the Turkish 
saddle and a similar 7 × 4 × 5 mm lesion on the left, in 
direct proximity to cavernous sinuses (Fig. 2). Also in 2015, 
a routine abdominal ultrasound revealed bilateral adrenal 
tumours. A low-density 25 × 16 × 21 mm tumour in the 
right adrenal gland and a similar 13 mm focal lesion in 
the left adrenal were confirmed in abdominal computed 
tomography (CT) (Fig. 3). Endocrinological evaluation 
detected no abnormal hormonal function of the adrenal 
tumours. Currently, at the age of 68 years, persistent 
elevation of PTH was confirmed, with normal calcium 
and phosphate concentrations and vitamin D level within 
the normal range. No focal lesions suggestive of enlarged 
parathyroid glands were revealed by neck ultrasound 
nor control 99mTc-MIBI SPECT-CT. Densitometry showed 
osteopaenia of the lumbar vertebral column and proximal 
part of the arm, while nephrolithiasis and cholecystoli-
thiasis were diagnosed in abdominal ultrasound. Insuf-
ficiency of the thyroid axis was diagnosed, and l-thyroxine 
substitution was implemented. Due to clinical manifesta-
tion of two characteristic features of MEN1 syndrome, 
genetic testing was performed. Sanger sequencing 
confirmed the MEN1 variant p.Val167Ala — a missense 
variant registered in NCBI dbSNP under the accession 
number rs748648909. In NCBI ClinVar, it was summarised 
to be of uncertain clinical significance (RCV000632131.2). 
So far, this variant has not been described in HGMD and 
UMD-MEN1 databases. The patient’s family members 
have been invited for cascade screening. 
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Multiple neuroendocrine neoplasia type 1 is a rare ge-
netic disorder with an autosomal dominant inheritance. 
The MEN1 gene, located on chromosome 11q13, encodes 
the protein menin, which directly regulates expression 
of the cyclin-dependent kinase-inhibiting (CKI) genes 
CDKN1b (encoding p27) and CDKN2C (encoding p18). 
Up to 1336 MEN1 gene sequence abnormalities were 
described within only 10 years following the identifica-
tion of the gene [1]. In the case of clinical presentation 
of MEN1 but no detectable MEN1 mutation, MEN4 
should be suspected. It is also referred to as MENX and 
is caused by heterozygous mutations of CDNK1B [2].
The phenotype-genotype correlation among MEN1 
patients in terms of tumour localisation, age of onset, 
and clinical aggressiveness has not been established yet 
[2]. Usually the first manifestation of MEN1 syndrome 
is PHP, with almost 100% penetrance up to the age of 
50 years. In our case, onset of PHP has been estimated 
at the age of 56 years. Even mild hypercalcaemia in pa-
tients presenting with MEN1-associated features should 
heighten awareness among health care practitioners [3]. 
Acromegaly related to MEN1 is diagnosed in about 10% 
of cases. MEN 1-associated somatotroph pituitary tu-
mours are often macroadenomas with local aggressive-
ness and poor response to various treatment modalities 
[4]. Adrenal involvement among MEN1 patients should 
also heighten awareness, because those adrenal lesions 
tend to differ from sporadic incidentalomas. The rela-
tively high frequency of primary hyperaldosteronism 
but also rare cases of pheochromocytoma (constituting 
pituitary adenoma/pheochromocytoma/paraganglioma 
association [3Pa]) should be considered during endo-
crinological evaluation [5]. 
Further follow-up of the patient and her family 
members should be carried out to confirm the spectrum 
and exact time of clinical presentation and, therefore, 
to determine the clinical significance of this rare MEN1 
gene variant (p.Val167Ala).
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Figure 1. Clinical presentation of the patient — acral enlargement
Figure 3. Coronal CT image of the abdomen. Tumour of the right 
adrenal gland (arrow)
Figure 2. Coronal MRI image of the hypothalamic-pituitary area. 
Dominating radiological image of an empty sella. Remnants of 
the pituitary gland, less than 1 mm in diameter, at the bottom of 
the sella turcica and two hypointense masses 11 × 8 × 13 mm 
in the right lateral part of the Turkish saddle and a similar 7 × 4 
× 5 mm lesion on the left, in direct proximity to cavernous sinuses
